TY - JOUR
T1 - Luteinizing hormone-releasing hormone (LHRH) conjugated magnetite nanoparticles as MRI contrast agents for breast cancer imaging
AU - Hu, Jingjie
AU - Obayemi, John
AU - Malatesta, Karen
AU - Yurkow, Edward
AU - Adler, Derek
AU - Soboyejo, Winston
N1 - Funding Information:
Funding: This research was funded by Princeton University’s Old School Fund (Grant No. 25105-B0635-FA572) and the World Bank African Centers of Excellence (PAMI Grant No. P126974).
Funding Information:
This research was funded by Princeton University's Old School Fund (Grant No. 25105-B0635-FA572) and the World Bank African Centers of Excellence (PAMI Grant No. P126974). The authors acknowledge Xue Zhou and Adekunle Adeyeye (National University of Singapore) for VSM measurements. The authors are also grateful to Princeton University, Rutgers University, and Worcester Polytechnic Institute for their technical support.
Publisher Copyright:
© 2020 by the authors.
PY - 2020/8
Y1 - 2020/8
N2 - Targeted magnetic resonance imaging (MRI) contrast agents offer platforms for the specific detection of many diseases, including cancer. This study explores the applicability of luteinizing hormone-releasing hormone-conjugated PEG-coated magnetite nanoparticles (LHRH-MNPs) to the enhancement of triple negative breast cancer (TNBC) detection. In vitro MRI studies were first performed, showing the consistent darkening effect of both MNPs and LHRH-MNPs in T2-weighted maps. Using a mouse model with an induced subcutaneous tumor, MNPs and LHRH-MNPs were injected into xenograft MDA-MB-231. This was done through intratumoral and intravenous injections, respectively, enabling direction comparisons of the two nanoparticles. Intratumorally injected LHRH-MNPs maintained T2 signals within the breast tumors up to two weeks, revealing long-term tumor enhancement ability, while the signal started to recover towards the contrast of the original tumor before injection in the case of MNPs at 24 h post injection. For intravenous administration, LHRH-MNPs continued to darken breast tumor 24 h following injection, whereas contrast enhancement was not obvious in animals injected with MNPs. These results show the potential of LHRH-MNPs as negative contrast agents for the specific detection of TNBC.
AB - Targeted magnetic resonance imaging (MRI) contrast agents offer platforms for the specific detection of many diseases, including cancer. This study explores the applicability of luteinizing hormone-releasing hormone-conjugated PEG-coated magnetite nanoparticles (LHRH-MNPs) to the enhancement of triple negative breast cancer (TNBC) detection. In vitro MRI studies were first performed, showing the consistent darkening effect of both MNPs and LHRH-MNPs in T2-weighted maps. Using a mouse model with an induced subcutaneous tumor, MNPs and LHRH-MNPs were injected into xenograft MDA-MB-231. This was done through intratumoral and intravenous injections, respectively, enabling direction comparisons of the two nanoparticles. Intratumorally injected LHRH-MNPs maintained T2 signals within the breast tumors up to two weeks, revealing long-term tumor enhancement ability, while the signal started to recover towards the contrast of the original tumor before injection in the case of MNPs at 24 h post injection. For intravenous administration, LHRH-MNPs continued to darken breast tumor 24 h following injection, whereas contrast enhancement was not obvious in animals injected with MNPs. These results show the potential of LHRH-MNPs as negative contrast agents for the specific detection of TNBC.
KW - Cancer detection
KW - Luteinizing hormone-releasing hormone (LHRH)
KW - Magnetic resonance imaging (MRI)
KW - Magnetite nanoparticles
KW - Triple negative breast cancer (TNBC)
UR - http://www.scopus.com/inward/record.url?scp=85088803439&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85088803439&partnerID=8YFLogxK
U2 - 10.3390/app10155175
DO - 10.3390/app10155175
M3 - Article
AN - SCOPUS:85088803439
VL - 10
JO - Applied Sciences (Switzerland)
JF - Applied Sciences (Switzerland)
SN - 2076-3417
IS - 15
M1 - 5175
ER -